Venlafaxine-Induced Urinary Retention

References (9)

1. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord. 1998;51(3):237–254. PubMed CrossRef NLM
2. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc. 2001;76(5):511–527. PubMed CrossRef NLM
3. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol. 1996;16(suppl 2):54S–59S, discussion 59S–61S. PubMed CrossRef NLM
4. Kelsey JE. Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder. Depress Anxiety. 2000;12(suppl 1):81–84. PubMed CrossRef NLM
5. Benazzi F. Urinary retention with venlafaxine-haloperidol combination. Pharmacopsychiatry. 1997;30(1):27. PubMed CrossRef NLM
6. Benazzi F. Venlafaxine-fluoxetine interaction. J Clin Psychopharmacol. 1999;19(1):96–98. PubMed CrossRef NLM
7. Benazzi F. Anticholinergic toxic syndrome with venlafaxine-desipramine combination. Pharmacopsychiatry. 1998;31(1):36–37. PubMed CrossRef NLM
8. Miller T, McGoodwin L, Hagemann T. Anticholinergic-type effects following a pediatric venlafaxine overdose. Clin Toxicol (Phila). 2008;46(4):338–339. PubMed CrossRef NLM
9. Bae JH, Moon DG, Lee JG. The effects of a selective noradrenaline reuptake inhibitor on the urethra: an in vitro and in vivo study. BJU Int. 2001;88(7):771–775. PubMed CrossRef NLM